Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): VRDN-001

            Therapeutic Area: Ophthalmology Product Name: AVE-1642

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: Fairmount Funds Management LLC

            Deal Size: $91.0 million Upfront Cash: Undisclosed

            Deal Type: Financing October 28, 2020

            Details:

            Company plans to use private placement financing proceeds of $91 million to advance multiple compounds through phase 2 proof of concept studies in TED and to expand its orphan disease pipeline

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): EO2002

            Therapeutic Area: Ophthalmology Product Name: EO2002

            Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 22, 2020

            Details:

            The active IND enables Emmecell to initiate a Phase 1 clinical trial designed to assess the tolerability, safety, and efficacy of EO2002 in patients with corneal edema.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Axitinib

            Therapeutic Area: Ophthalmology Product Name: CLS-AX

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 10, 2020

            Details:

            Phase 1/2a trial in wet AMD patients is expected to be an open-label, dose-escalation study to assess the safety and tolerability of single doses of CLS-AX administered through suprachoroidal injection after two or more prior treatments with an intravitreal anti-VEGF agent.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Axitinib

            Therapeutic Area: Ophthalmology Product Name: CLS-AX

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 27, 2020

            Details:

            Multiple posters and oral presentations on Clearside’s pipeline and its proprietary SCS Microinjector® targeting the suprachoroidal space (SCS®) were delivered at the American Society of Retina Specialists (ASRS) 2020 Virtual Annual Meeting.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CAP4196

            Therapeutic Area: Ophthalmology Product Name: CAP4196

            Highest Development Status: IND Enabling Product Type: Undisclosed

            Partner/Sponsor/Collaborator: National Institutes of Health

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Funding July 08, 2020

            Details:

            Under the Phase II grant, Plex intends to advance its lead anti-cataract drug candidate, CAP4196 through preclinical and IND enabling studies to gain clearance from the FDA to initiate its first-in-human clinical trials for the non-surgical treatment of cataracts.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Axitinib

            Therapeutic Area: Ophthalmology Product Name: Undisclosed

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 25, 2020

            Details:

            Suprachoroidal injection platform featured in multiple indications including wet AMD, uveitis, diabetic macular edema, and ocular gene therapy.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TTHX1114

            Therapeutic Area: Ophthalmology Product Name: Undisclosed

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: Trefoil Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration February 04, 2020

            Details:

            AGC Biologics will assist Trefoil Therapeutics with the production of their life changing product, TTHX1114, engineered form of FGF-1 to restore lost vision in patients with corneal diseases.